SKP2 and cancer: Therefore, our study highlights safranal as a potential therapeutic agent for Pca recurrence and provides evidence that pharmacological inactivation of the NF-κB/E2F1–Skp2 axis is a potential therapeutic target against cancer recurrence and progression.